• Investors may be wondering whether Pulse Biosciences, at around US$23 per share, still offers value or whether most of the opportunity is already reflected in the price.
• The stock shows returns of 7.0% over 7 days, 28.1% over 30 days, 71.8% year to date and 58.3% over 1 year. These figures naturally raise questions about what is already priced in and how much risk you are taking on at current levels.
• Recent attention on Pulse Biosciences has centered on its position in the medical equipment space and how the market is reacting to its progress and prospects. This broader interest provides useful context when considering whether the recent share price moves align with the company’s fundamentals.
• Despite these strong recent returns, Pulse Biosciences currently has a valuation score of 0 out of 6. The next step is to look at how different valuation approaches assess the stock today and then consider an even more complete way of thinking about value at the end of this article.

Pulse Biosciences scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Pulse Biosciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return to arrive at an estimate of intrinsic value per share.

For Pulse Biosciences, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $54.7 million. Analyst input and extrapolated estimates suggest free cash flows staying negative for several years, then turning positive to about $10 million in 2030, with further increases projected through 2035 based on Simply Wall St’s extrapolations.

When all of those projected cash flows are discounted back to today in this model, the estimated intrinsic value comes out at around $2.61 per share. Compared with the current share price of about $23, the implied gap is very large, and the DCF output suggests the shares are very fully priced at current levels.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Pulse Biosciences may be overvalued by 781.9%. Discover 62 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Pulse Biosciences Price vs Book

For companies where earnings are not yet a clear guide, price to book, or P/B, is often used because it compares what you pay per share with the accounting value of the net assets backing that share.

In general, higher growth expectations and lower perceived risk can justify a higher multiple, while weaker growth or higher risk usually point to a lower or more moderate “normal” ratio. That is why investors often compare a stock’s multiple to sector norms before judging whether it looks stretched or conservative.

Pulse Biosciences currently trades on a P/B of 19.39x, versus the Medical Equipment industry average of 2.28x and a peer average of 1.67x. Simply Wall St’s “Fair Ratio” is a proprietary estimate of what a reasonable P/B might be, given factors such as earnings growth profile, profit margins, market cap, industry and specific risks. This tailored yardstick can be more useful than a simple peer or industry comparison because it adjusts for company-specific characteristics rather than assuming all businesses should share the same benchmark multiple. As the Fair Ratio for Pulse Biosciences is not available, it is not possible to use this framework to judge whether the current P/B looks high, low or about right.

Result: OVERVALUED

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Pulse Biosciences Narrative

Earlier it was mentioned that there is an even better way to think about valuation, so Narratives are introduced here as a simple way for you to attach your own story about Pulse Biosciences, including your assumptions for future revenue, earnings and margins, to a set of financial forecasts that produce a Fair Value you can compare directly with the current share price.

On Simply Wall St, Narratives sit inside the Community page and are designed so that any investor can quickly connect a clear thesis about a company to the numbers behind it, see what Fair Value that story implies, and then decide whether the current market price looks high or low relative to that view.

Narratives also update as fresh information such as news, clinical trial results or earnings is added to the platform, so your Fair Value estimate can keep pace with what is happening without you rebuilding a model each time.

For Pulse Biosciences, one Narrative might align with a higher Fair Value of US$30 per share based on an optimistic view of revenue potential and margins. Another might anchor closer to US$22, and seeing these side by side helps you decide which story, and which Fair Value, best matches your own expectations.

For Pulse Biosciences, however, we will make it really easy for you with previews of two leading Pulse Biosciences Narratives:

Fair Value: US$30.00

Implied valuation gap vs last close: around 23% below this fair value level, based on a last close of US$23.00 compared with the US$30.00 narrative fair value.

Revenue growth assumption: very large annual increase implied by a 689.54% figure, reflecting an aggressive growth outlook in this scenario.

• Views the early Vybrance thyroid business, with initial revenue and over 200 patients treated, as the start of a larger procedure and disposable base over time.
• Assumes that current quarterly cash use of about US$13.0m and a GAAP net loss of US$19.4m eventually translate into future revenue streams as cardiac and thyroid programs move through clinical and regulatory steps.
• Requires confidence that by around 2029, revenue could reach about US$42.3m with earnings of US$5.7m on an industry-like profit margin, and that the market would support a very high P/E multiple on those earnings.

Fair Value: US$22.00

Implied valuation gap vs last close: the last close of US$23.00 sits about 5% above this fair value level.

Revenue growth assumption: very large annual increase implied by a 601.51% figure, still a strong growth view even in this more cautious scenario.

• Recognizes progress in thyroid and cardiac programs, but treats the limited revenue base alongside quarterly costs of US$20.5m as a key constraint until sales scale.
• Highlights reliance on reimbursement, guideline inclusion and competitive positioning in atrial fibrillation, all of which could influence how much of the projected revenue and margin improvement is achieved.
• Builds in the possibility that high operating expenses, clinical timelines and potential funding needs could leave earnings and cash flows under pressure even if revenue grows quickly.

Do you think there's more to the story for Pulse Biosciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.